Atossa Genetics (ATOS) Announces Novel Approach to Adaptive T-cell Therapy In Breast Cancer Today!

With the recent kick-off of the Annual Breast Cancer Awareness Month in October, it is fair to say that we are making strides in the fight, but there is much to be accomplished. The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017.

Today we would like to highlight the fact that the transpapillary (TRAP) delivery of therapeutics in breast cancer clinical trials have demonstrated “that cytotoxic drugs can be safely administered into breast ducts with minimal toxicity” Zhang B, et al. Chin J Cancer Res. 2014 Oct;26(5):579-87 .

T cells are removed from a patient and modified so that they express receptors specific to the patient’s particular breast cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient using a microcatheter into the natural ducts of the breast.

Chimeric antigen receptors (or, “CARs” and also known as chimeric immunoreceptors, chimeric T cell receptors, artificial T cell receptors or CAR-T) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T cell). Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell, with the transfer of their coding sequence facilitated by retroviral vectors. The receptors are called chimeric because they are composed of parts from different sources.

CAR-T technology has been the subject of much attention recently as pioneer CAR-T company Kite Pharma (KITE) recently announced its acquisition by Gilead (GILD), and the FDA has recently approved Novartis’s Kymriah™ for treatment of B-cell Acute Lymphoblastic Leukemia.

Atossa Genetics (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced also today news about a new program using Chimeric Antigen Receptor Therapy, or CAR-T. Atossa plans to use its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer.

Atossa’s novel approach uses its proprietary intraductal microcatheter technology for the potential transpapillary, or “TRAP,” delivery of T-cells that have been genetically modified to attack breast cancer cells. Atossa believes this method has several potential advantages: reduced toxicity by limiting systemic exposure of the T-cells; improved efficacy by placing the T-cells in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells along the same path taken by migrating cancer cells, potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. Atossa’s approach is in the research and development phase and has not been approved by the FDA or any other regulatory body. Pre-clinical studies, and clinical studies demonstrating safety and efficacy among other things, and regulatory approvals will be required before commercialization.

Steven Quay, MD, PhD, Atossa CEO stated, “We have been encouraged by the promise that CAR-T has shown in other forms of cancer, which is usually delivered systemically. We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T. We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T-cell therapy in breast cancer, will provide another approach to breast cancer, and that it may be particularly well-suited for the deadlier forms of breast cancer such as ‘triple negative.’ Now that we have developed a foundational intellectual property position with respect to TRAP CAR-T, we intend to continue research and development through partnership with leading investigators, institutions, and organizations around the world, bringing Atossa’s technology and expertise in TRAP delivery together with experts in cancer immunology and T-cell biology. Multiple studies in both animals and humans have shown that a number of therapeutics can be delivered by the TRAP, intraductal route.”

WHAT WE KNOW ABOUT TRAP IN BREAST CANCER

The transpapillary (TRAP) delivery of therapeutics in breast cancer clinical trials have demonstrated “that cytotoxic drugs can be safely administered into breast ducts with minimal toxicity” Zhang B, et al. Chin J Cancer Res. 2014 Oct;26(5):579-87 .

T cells are removed from a patient and modified so that they express receptors specific to the patient’s particular breast cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient using a microcatheter into the natural ducts of the breast.

Chimeric antigen receptors (or, “CARs” and also known as chimeric immunoreceptors, chimeric T cell receptors, artificial T cell receptors or CAR-T) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T cell). Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell, with the transfer of their coding sequence facilitated by retroviral vectors. The receptors are called chimeric because they are composed of parts from different sources.

CAR-T technology has been the subject of much attention recently as pioneer CAR-T company Kite Pharma (KITE) recently announced its acquisition by Gilead, and the FDA has recently approved Novartis’s Kymriah™ for treatment of B-cell Acute Lymphoblastic Leukemia.

To learn more about Atossa Genetics, Inc. (ATOS) and to track its progress please visit the Vista Partners Company Dedicated Page.

Press Releases | Atossa Genetics, Inc. (ATOS)

..

ir.atossagenetics.com

Read Full Article



Health Insurance Innovations, Inc. (HIIQ) Reaffirms Financial Outlook for Full Year 2017

Tampa, FL based Health Insurance Innovations, Inc. (HIIQ) has delivered nine straight quarters of record revenue and adjusted earnings.

This week HIIQ reaffirmed its previously announced and revised full year 2017 guidance and expects to achieve the following results:

  • Revenue growth of 22% to 25% year-over-year ($225 million to $230 million);
  • Adjusted EBITDA growth of 41% to 51% year-over-year ($39 million to $42 million);
  • and Adjusted EPS growth of 29% to 38% ($1.45 to $1.55).

HIIQ is a market leader in developing innovative health insurance products that are affordable and meet the needs of millions of health insurance plan shoppers. HIIQ develops insurance products through partnerships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation. HII’s data-centric paperless business model is facilitated by its Consumer Division that provides real-time data used to identify opportunities and underserved needs in the health insurance market. HIIQ’s Consumer Division includes AgileHealthInsurance.com, a website for researching, comparing and purchasing Term Health insurance products and HealthPocket.com, an independently managed free website that compares and ranks all health insurance plans, and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

To learn more about HIIQ and track the companies progress, please Visit HIIQ’s Company Dedicated Page on Vista Partners’ Website by clicking here.

Health Insurance Innovations, Inc. Highlights Strength of Business

Provides Update on Montana Regulatory Matter and Florida TPA Licensure Process. Reaffirms Financial Outlook for Full Year 2017. TAMPA, Fla., Sept. 27, 2017– Health Insurance Innovations, Inc., a leading …..

finance.yahoo.com

Read Full Article



Breast Cancer Innovator Atossa Genetics (ATOS) Presenting in New York City October 5, 2017

Seattle, WA based Atossa Genetics Inc. (NasdaqCM: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Today Atossa announced that Kyle Guse, CFO, will be a featured presenter at The MicroCap Conference on Thursday October 5, 2017 at 12:30 PM Eastern Time. The conference is being held at the Essex House in New York City.

Earlier this week, Atossa announced that it had contracted with a leading European hospital to conduct a Phase 2 study of its proprietary topical Endoxifen for the treatment of women with mammographic breast density, or MBD. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer. The Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

Atossa plans to apply for approval from the Institutional Review Board and Swedish regulatory authority (Medical Products Agency) within the next 30 days. The placebo-controlled, double-blinded study is expected to enroll up to 480 subjects. The primary endpoint is MBD reduction, which will be measured after six and twelve months of dosing, as well as safety and tolerability.

To learn more about Atossa Genetics Inc. (NasdaqCM: ATOS) and to track its progress please visit the Vista Partners’ Company Dedicated Page.

Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017

SEATTLE, Sept. 29, 2017– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced …..

finance.yahoo.com

Read Full Article



FDA Grants Priority Review for Roche’s Perjeta in Breast Cancer

Exciting news hit the tape today in the world of breast cancer treatment & heading into the annual Breast Cancer Awareness Month that is kicking off in October. Roche officials reported that the FDA has granted priority review for Roche’s Perjeta specifically in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery. The Reuters article stated that FDA is expected to make a decision on approval by Jan 28, 2018.

The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017.

Breast Cancer Awareness Month is an annual campaign to raise awareness of breast cancer risks, the value of screening and early detection, and treatment options available to women and men who are diagnosed with one of the many forms of breast cancer.

Roche’s Perjeta regimen gets FDA priority review in breast cancer

The U.S. Food and Drug Administration has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche …..

finance.yahoo.com

Read Full Article



Leading Breast Cancer Researcher Spearheading Atossa Genetics (ATOS)’s Topical Endoxifen Phase 2 Trial for MBD

The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed, and 460 men will die from breast cancer in 2017.

Seattle, WA based Atossa Genetics Inc. (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions is developing its proprietary topical Endoxifen to reduce MBD, which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 30 U.S. states require that findings of MBD be directly communicated to the patient. Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most physicians and their patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risk of, or actual side-effects of, oral tamoxifen.

Today, ATOS announced that it has contracted with a leading European hospital to conduct a Phase 2 study of its proprietary topical Endoxifen for the treatment of women with mammographic breast density or MBD. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer. The Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Stockholm South General Hospital is one of the largest hospitals in Sweden, offering care to more than two million Stockholmers. It is one of four hospitals collaborating with Karolinska on the KARMA project. For more information, please visit http://www.sodersjukhuset.se/Functions/InEnglish/.  Karolinska Institutet, located in Stockholm, Sweden, is one of the world’s foremost medical universities. Its vision is to make a significant contribution to the improvement of human health; its mission is to conduct research and education and to interact with the community. As a university, KI is Sweden’s single largest center of medical academic research and offers the country’s widest range of medical courses and programs. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. For more information, please visit www.ki.se/en and www.KARMAstudy.org.

Dr. Steven C. Quay, CEO and President of Atossa Genetics stated, “Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is heading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies about breast cancer risk assessment and prevention, and the Karisma Intervention Study, which is studying the change in MBD in women taking various doses of oral tamoxifen. We are honored to be working with Dr. Hall and his colleagues on our Phase 2 study of MBD as their unique experience and qualifications are simply unmatched anywhere in the world.”

Atossa plans to apply for approval from the Institutional Review Board and Swedish regulatory authority (Medical Products Agency) within the next 30 days. The placebo-controlled, double-blinded study is expected to enroll up to 480 subjects. The primary endpoint is MBD reduction, which will be measured after six and twelve months of dosing, as well as safety and tolerability.

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Atossa has completed a comprehensive Phase 1 clinical study using both a topical and an oral formulation of Endoxifen. Preliminary results from the topical arm of the study indicated that the topical formulation was safe, well tolerated and that topical Endoxifen crossed the skin barrier in a dose-dependent fashion.

Approximately one million breast cancer survivors take oral tamoxifen annually; however, up to half of them do not properly metabolize tamoxifen and do not have desired levels of Endoxifen (meaning they are “refractory”). Low Endoxifen levels in breast cancer patients taking oral tamoxifen are associated with an increased risk of recurrence or the development of new breast tumors. Providing oral Endoxifen directly to the patient without having to be metabolized by the liver may help to address this problem.

Based on the number of women at high-risk of developing breast cancer and the number of patients who have survived breast cancer but are refractory to tamoxifen, Atossa estimates that the potential markets for its proprietary oral and topical formulations of Endoxifen could each potentially exceed $1 billion in annual sales.

 To learn more about Atossa Genetics Inc. (NasdaqCM: ATOS) and to track its progress please visit the Vista Partners’ Company Dedicated Page.

Atossa Genetics Announces Upcoming Phase 2 Study of Topical Endoxifen

SEATTLE, Sept. 25, 2017– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions has contracted with …..

finance.yahoo.com

Read Full Article



Warby Parker Now Accepting Vision Insurance Enabling Millions To Purchase Prescription Eyewear for Copay

Dave Gilboa, co-founder and co-CEO of Warby Parker stated, “Warby Parker is constantly exploring new ways to provide people access to affordable, high-quality and fashionable eyewear. We look forward to working with UnitedHealthcare, nationwide, to enable millions of Americans to purchase their eyewear at a fraction of the price they might pay through traditional channels.”  Warby Parker was founded with a rebellious spirit and a lofty objective: to offer designer eyewear at a revolutionary price, while leading the way for socially conscious businesses. Every idea starts with a problem. Theirs was simple: glasses are too expensive. By circumventing traditional channels, designing glasses in-house, and engaging with customers directly, they’re able to provide higher-quality, better-looking prescription eyewear starting at $95 (a fraction of the going price). Warby Parker also believes that everyone has the right to see. Almost one billion people worldwide lack access to glasses, which means that 15% of the world’s population cannot effectively learn or work. To help address this problem, Warby Parker partners with non-profits like VisionSpring to ensure that for every pair of glasses sold, a pair is distributed to someone in need.

As people now enter the open enrollment season for 2018 health benefits, this new relationship will help meet the eye-care needs for UnitedHealthcare plan participants nationwide.

Tom Wiffler, CEO, UnitedHealthcare Specialty Benefits stated, “Warby Parker and UnitedHealthcare will help more Americans access designer eyewear at affordable prices to help meet the eye-care needs of the people we serve. We are grateful Warby Parker selected UnitedHealthcare to be its first in-network vision plan.”UnitedHealthcare is dedicated to helping people nationwide live healthier lives by simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. The company offers the full spectrum of health benefit programs for individuals, employers, military service members, retirees and their families, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1 million physicians and care professionals, and 6,000 hospitals and other care facilities nationwide. UnitedHealthcare is one of the businesses of UnitedHealth Group (UNH), a diversified Fortune 50 health and well-being company.

UnitedHealthcare is dedicated to helping people nationwide live healthier lives by simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. The company offers the full spectrum of health benefit programs for individuals, employers, military service members, retirees and their families, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1 million physicians and care professionals, and 6,000 hospitals and other care facilities nationwide. UnitedHealthcare is one of the businesses of UnitedHealth Group (UNH), a diversified Fortune 50 health and well-being company.

To learn more about Minnetonka, Minnesota based UnitedHealth Group (NYSE: UNH) and to track its progress please visit the Vista Partners’ Company Dedicated Page.

Warby Parker and UnitedHealthcare Collaboration to Feature Affordable, Designer Prescription Eyewear

People enrolled in UnitedHealthcare employer-sponsored and individual vision plans can access Warby Parker’s designer prescription eyewear at affordable prices, online or at any of the more than 50 stores nationwide, beginning in 2018…

finance.yahoo.com

Read Full Article



Merck’s KEYTRUDA Now FDA Approved for Previously Treated Patients w/ Recurrent Locally Advanced Cancer Whose Tumors Express PD-L1

Dr. Roger M. Perlmutter, president, Merck Research Laboratories stated “KEYTRUDA is now the first PD-1 checkpoint inhibitor approved in the United States for previously treated advanced gastric or GEJ cancer, helping to address a recognized treatment gap. This approval marks another milestone – the tenth new indication for KEYTRUDA in just three years – which further demonstrates both our commitment to patients and the progress we have made in the fight against many cancers.”

Formally on September 22nd, Merck ( NYSE: MRK) announced that The U.S. Food and Drug Administration (FDA) has approved  KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under the FDA’s accelerated approval regulations based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

“Historically, advanced gastric cancer has been particularly challenging to treat, and new treatment options are needed for these patients,” said Charles S. Fuchs, M.D., MPH, lead investigator, and director of Yale Cancer Center. “The results observed in the diverse population of heavily pretreated advanced gastric or GEJ patients from the KEYNOTE-059 clinical trial demonstrate that pembrolizumab in the third-line setting has the potential to shift how we care for certain patients facing this difficult-to-treat disease.”

The accelerated approval for KEYTRUDA was reported to be based on data from a global, multicenter, non-randomized, open-label multi-cohort trial, KEYNOTE-059, that enrolled 259 patients with gastric or GEJ adenocarcinoma who progressed on at least two prior systemic treatments for advanced disease. Previous treatment must have included a fluoropyrimidine and platinum doublet; HER2/neu-positive patients must have previously received treatment with approved HER2/neu-targeted therapy. Patients with active autoimmune disease or a medical condition that required immunosuppression or with clinical evidence of ascites by physical exam were ineligible. Patients received KEYTRUDA at a dose of 200 mg every three weeks until unacceptable toxicity or disease progression that was symptomatic, rapidly progressive, required urgent intervention, occurred with a decline in performance status or was confirmed at least four weeks later with repeat imaging. Patients without disease progression were treated for up to 24 months. Assessment of tumor status was performed every six to nine weeks. The major efficacy outcome measures were objective response rate (ORR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by an independent central review, and duration of response.

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industry’s largest immuno-oncology clinical research program, which currently involves more than 550 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefiting from treatment with KEYTRUDA, including exploring several different biomarkers.

To learn more about Merck (NYSE: MRK) and to track their progress please visit Vista Partners Dedicated Company Page.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA® , the company’s anti-PD-1 therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma..

finance.yahoo.com

Read Full Article



Health Insurance Innovations (HIIQ) Presents “9 Straight Quarters of Record Revenue & Adjusted Earnings”

Tampa, FL based Health Insurance Innovations, Inc. (NasdaqCM: HIIQ) is a market leader in developing innovative health insurance products that are affordable and meet the needs of millions of health insurance plan shoppers. HIIQ develops insurance products through partnerships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation. HIIQ’s data-centric paperless business model is facilitated by its Consumer Division that provides real-time data used to identify opportunities and underserved needs in the health insurance market. HIIQ’s Consumer Division includes AgileHealthInsurance.com, a website for researching, comparing and purchasing Term Health insurance products and HealthPocket.com, an independently managed free website that compares and ranks all health insurance plans, and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

HIIQ’s Gavin Southwell, CEO and President and Michael Hershberger, CFO are presenting today, Monday, September 25, 2017, at the  Cantor Fitzgerald Global Healthcare Conference in New York City.  The presentation is scheduled for 3:00 p.m. EDT at the InterContinental New York Barclay Hotel.

HIIQ’s management will speak to their progress and will use their latest presentation that was recently filed via 8k and that can be accessed via the SEC website:  www.sec.gov. The presentation highlights among other progress that they have achieved (Slide 14) “9 Straight Quarters of Record Revenue & Adjusted Earnings”.

To learn more about HIIQ and track the companies progress, please Visit HIIQ’s Company Dedicated Page on Vista Partners’ Website by clicking here.

 




Health Insurance Innovations (HIIQ) To Present at Cantor Fitzgerald Global Healthcare Conference Monday September 25th In NYC!

Tampa, FL based Health Insurance Innovations, Inc. (NasdaqCM: HIIQ) is a market leader in developing innovative health insurance products that are affordable and meet the needs of millions of health insurance plan shoppers. HIIQ develops insurance products through partnerships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation. HII’s data-centric paperless business model is facilitated by its Consumer Division that provides real-time data used to identify opportunities and underserved needs in the health insurance market. HIIQ’s Consumer Division includes AgileHealthInsurance.com, a website for researching, comparing and purchasing Term Health insurance products and HealthPocket.com, an independently managed free website that compares and ranks all health insurance plans, and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

HIIQ’s Gavin Southwell, CEO and President and Michael Hershberger, CFO, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City. The presentation is scheduled for Monday, September 25, 2017 at 3:00 p.m. EDT at the InterContinental New York Barclay Hotel.

To Visit HIIQ’s Company Dedicated Page on Vista Partners’ Website, please click here.

Health Insurance Innovations to Present at Cantor Fitzgerald Global Healthcare Conference in New York

TAMPA, Fla., Sept. 14, 2017– Health Insurance Innovations, Inc., a leading developer, distributor, and cloud-based administrator of affordable health insurance and supplemental plans, announced today …..

finance.yahoo.com

Read Full Article



“Wild & Crazy?” Or “Calm & Sane?”

No we are not suggesting that the woman pictured is “Wild & Crazy”  or  for that matter “Calm & Sane”, but we are confirming that Vista Partners Weekly Market Update for Week Ending September 2017 called “Wild & Crazy” is available. It includes a quick overview & results of the markets for the week written by Managing Director, John F. Heerdink, Jr., and news, trending videos from Vista Partners Coverage Universe that includes all components of the Dow 30 and a Select Group of Emerging Growth Companies and beyond. The Weekly Market Update is targeted to be published on the Vista Partners website and emailed out to all registered by each weekend. Please take a few seconds to register to receive this free publication directly to your email weekly and to be to download the current newsletter in pdf form now at the “newsletters” section of the Vista Partners website www.vistapglobal.com.

Vista Partners also hosts dedicated pages for the Coverage Universe that includes the all of the companies in the Dow 30 and a Select Group of Emerging Growth Companies. These pages can assist in gaining greater understanding and insights across a variety of investments and ventures.

Please do not forget to send Vista Partners your investment ideas for our consideration and to receive the chance to be added to our newsletter and the Vista Partners Coverage Universe.  Company management, board members, investor relations firms, & investors may also simply complete the Vista Partners quick & EASY FORM or send Vista Partners an email at inquiries@vistapglobal.com for consideration of being added to the Vista Partners Coverage Universe.

We hope you enjoy and thank you for your continued attention.

Based in San Francisco, CA Vista Partners LLC (“Vista”) was founded in 2005 and is a Registered Investment Advisor in the State of California. Vista seeks to invest partner capital with a global perspective across all sectors, provide advice to issuers regarding fundamental development, corporate governance, and capital market directives, while providing a platform for all to discover timely and relevant insights and information to foster further evaluation & understanding with a goal of becoming a better investor.